These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37533709)

  • 41. Psychiatric Comorbidity and Stress in Medical Students Using Neuroenhancers.
    Jebrini T; Manz K; Koller G; Krause D; Soyka M; Franke AG
    Front Psychiatry; 2021; 12():771126. PubMed ID: 34975573
    [No Abstract]   [Full Text] [Related]  

  • 42. Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount.
    Banjo OC; Nadler R; Reiner PB
    PLoS One; 2010 Dec; 5(12):e14322. PubMed ID: 21179461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Souled out of rights? - predicaments in protecting the human spirit in the age of neuromarketing.
    Sieber A
    Life Sci Soc Policy; 2019 Nov; 15(1):6. PubMed ID: 31754881
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of and motives for pharmacological neuroenhancement in Switzerland--results from a national Internet panel.
    Maier LJ; Haug S; Schaub MP
    Addiction; 2016 Feb; 111(2):280-95. PubMed ID: 26189457
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PROTECTION OF HUMAN RIGHTS BY THE CONSTITUTIONAL COURT OF UKRAINE IN THE FIELD OF HEALTH CARE (REVIEW).
    Deshko L; Bysaga Y; Zaborovskyy V
    Georgian Med News; 2019 Sep; (294):165-171. PubMed ID: 31687971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. When is diminishment a form of enhancement? Rethinking the enhancement debate in biomedical ethics.
    Earp BD; Sandberg A; Kahane G; Savulescu J
    Front Syst Neurosci; 2014; 8():12. PubMed ID: 24550792
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Social impact and governance of AI and neurotechnologies.
    Doya K; Ema A; Kitano H; Sakagami M; Russell S
    Neural Netw; 2022 Aug; 152():542-554. PubMed ID: 35671575
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuroenhancement as Instrumental Drug Use: Putting the Debate in a Different Frame.
    Schleim S
    Front Psychiatry; 2020; 11():567497. PubMed ID: 33088276
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people.
    Boot BP; Partridge B; Hall W
    Neurocase; 2012 Jun; 18(3):181-4. PubMed ID: 22007842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurotechnology and ethics guidelines for human enhancement: The case of the hippocampal cognitive prosthesis.
    Erden YJ; Brey P
    Artif Organs; 2023 Aug; 47(8):1235-1241. PubMed ID: 37533179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Statutory caps: an involuntary contribution to the medical malpractice insurance crisis or a reasonable mechanism for obtaining affordable health care?
    Chupkovich PJ
    J Contemp Health Law Policy; 1993; 9():337-75. PubMed ID: 10126943
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Case of Pharmacological Neuroenhancement: Medical, Judicial and Ethical Aspects from a German Perspective.
    Franke AG; Northoff R; Hildt E
    Pharmacopsychiatry; 2015 Nov; 48(7):256-64. PubMed ID: 26252723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. "Sound law and undoubtedly good policy": Roe v. Wade in comparative perspective.
    Mylchreest I
    J Policy Hist; 1995; 7(1):53-71. PubMed ID: 12346345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Neuroenhancement].
    Gründer G; Bartsch T
    Nervenarzt; 2014 Dec; 85(12):1536-43. PubMed ID: 25403289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neurotechnologies, Ethics, and the Limits of Free Will.
    Adomaitis L; Grinbaum A
    Integr Psychol Behav Sci; 2024 Feb; ():. PubMed ID: 38388982
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Health in Chile's Recent Constitutional Process: A Qualitative Thematic Analysis of Civil Proposals.
    Cabieses B; Esnouf S; Blukacz A; Espinoza MA; Mezones-Holguin E; Leyva R
    Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554784
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice.
    Sayeed SA
    Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nutrition and national development: the case of Chile.
    Solimano G; Hakim P
    Int J Health Serv; 1979; 9(3):495-510. PubMed ID: 468441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.